DNA damage normally induces p53 activity, but responses to ionizing radiation in the mammary epithelium vary among developmental stages. The following studies examined the hormones and growth factors that regulate radiation-responsiveness of p53 in mouse mammary epithelium. Immunoreactive p21/WAF1 and TUNEL staining were used as indicators of p53 activity following exposure to ionizing radiation. In ovariectomized mice, radiation-induced accumulation of p21/WAF1 was minimal in the mammary epithelial cells (o1%). Systemic injections of estrogen and progesterone (E þ P) for 72 h were necessary to recover maximal expression of p21/ WAF1 following ionizing radiation (55%). The effects of E þ P on radiation-induced p21/WAF1 were p53-dependent as responses were absent in Trp53 À/À mice. Though hormonal treatments stimulated increases in the proportion of cycling cells (PCNA-positive), this was not directly correlated with p53 activity. Whole organ cultures were used to determine whether E þ P act directly upon the mammary gland. Treatment with E þ P was sufficient to render p53 responsive to radiation, but TGF-b-neutralizing antibodies blocked responsiveness. In the absence of E þ P, TGF-b1 alone did not alter p53 activity. These results demonstrate that estrogen and progesterone together with TGF-b signaling are necessary for maintenance of p53 activity in the mammary epithelium.
Introduction
One full-term pregnancy reduces the risk of breast cancer by up to 50% (Rosner et al., 1994) . The prophylactic effect of pregnancy can be mimicked by treatment with estrogen and progesterone in rodents (Sivaraman et al., 1998) . These ovarian steroids as well as the placental hormone human chorionic gonadotropin enhance radiation-induced apoptosis in mouse mammary epithelium through activation of p53 Sivaraman et al., 2001; Minter et al., 2002) . As these hormones have also been shown to prevent carcinogeninduced mammary tumors (Russo et al., 1990; Sivaraman et al., 1998) , it was proposed that regulation of p53 activity may mediate the protective effects of these hormones in the mammary epithelium. The absence of the parity-induced protection from tumors in p53-deficient mammary tissues provided direct evidence that the p53 pathway mediates the chemopreventive effects of these hormones. Consistent with the concept that p53 activity can modify risk, the p53 pathway was found to be refractory to radiationinduced DNA apoptosis in mammary epithelium of nulliparous mice Minter et al., 2002) . However, responses to radiation in mammary epithelium of nulliparous mice were further impaired in TGF-b1-deficient mice (Ewan et al., 2002a) , demonstrating a role for the TGF-b pathway in regulating p53. Like p53, expression of TGF-b in the mammary gland was responsive to changes in hormonal stimulation (Ewan et al., 2002b) . As both p53 and transforming growth factor b (TGF-b) can influence incidence of mammary tumors (Pierce Jr et al., 1995; Jerry et al., 2000) , these tumor suppressor pathways represent important regulators of both susceptibility and resistance to mammary tumors. Therefore, experiments were undertaken to determine the hormonal and growth factor requirements for activation of p53 in mouse mammary epithelium. The results demonstrate that the effects of estrogen and progesterone on p53 activity are inhibited by receptor antagonists and that TGF-b is required for optimal p53 activity. The inability of TGF-b to activate p53 in the absence of E þ P supports a cooperative mechanism involving crosstalk between these signaling pathways.
Results

Hormonal effects on p53 activity in vivo
The p53 tumor suppressor gene participates in cellular responses to a variety of cellular stresses and types of DNA damage, but is essential for directing cell cycle arrest and apoptosis in response to DNA double-strand breaks (Kastan et al., 1992) . Therefore, ionizing radiation was used to induce DNA double-strand breaks to examine the temporal effects of estrogen and progesterone on p53-dependent responses to DNA damage in ovariectomized mice. The cyclin-dependent kinase inhibitor p21/WAF1 is among the transcriptional targets of p53 and provides a direct indicator of p53 activity in the mammary epithelium (Jerry et al., 1998) . In unirradiated, ovariectomized controls, immunoreactive p21/WAF1 was o1% in all treatments providing a stable baseline to examine changes in p53-dependent responses to DNA damage. Radiation-induced expression of p21/WAF1 was increased progressively by treatment with E þ P for 24 h (3%), 48 h (26%) or 72 h (51%) (Figure 1a ; solid bars). Effects of E þ P on radiation-induced expression of p21/WAF1 were maximal at 72 h and were maintained through 96 h (55%). Immunoreactive p21/WAF1 was detected in nuclei of mammary epithelial cells throughout the ducts (Figure 1b) . This was in contrast to vehicle-treated mice where radiation-induced expression of p21/WAF1 was observed in less than 1% of mammary epithelial cells (Figure 1c ). Radiation-induced p21/WAF1 was also undetectable in BALB/c-Trp53
À/À mice treated with E þ P (Figure 1d) , demonstrating that the effects of the hormones on p21/WAF1 expression were p53-dependent. Nuclear accumulation of p53 accompanied radiation-induced expression of p21/WAF1 in mice treated with E þ P (Figure 1e ), but was absent in mice treated with Vehicle ( Figure 1f ). þ / þ females received daily injections of E þ P (2 mg and 1 mg, respectively) for 24, 48, 72 or 96 h. Error bars represent s.e.m. Immunohistochemical detection of p21/WAF1 in the mammary epithelium of mice irradiated after 72 h treatment with E þ P (b), vehicle alone (c), or BALB/c-Trp53 À/À mice treated with E þ P (d). Immunohistochemical detection of p53 in mammary gland epithelium of BALB/c-Trp53 þ / þ mice irradiated after 96 h treatment with E þ P (e) or vehicle alone (f). Immunohistochemical detection of PCNA in the mammary epithelium of BALB/c-Trp53 þ / þ mice irradiated after 96 h treatment with E þ P (g). Micrograph images represent Â 200 magnification As ovarian steroids also regulate growth of the mammary gland, proliferative responses were measured. Proliferating cell nuclear antigen (PCNA) was used as an indicator of cycling cells (Figure 1a , open bars). Basal levels of PCNA-positive mammary epithelial cells were o5% in ovariectomized mice treated with Vehicle alone. The proportion of PCNA-positive cells was increased by treatment with E þ P and followed the same temporal changes observed for the p21/WAF1 responses. Neither radiation treatment nor p53 genotype affected the number of nuclei staining positive for PCNA (data not shown). As with p21/WAF1, staining for PCNA was detected throughout the ducts (Figure 1g ). These results confirm that the hormonal treatments recruited cells into the cell cycle.
To determine the minimal hormonal treatment required to activate p53, ovariectomized mice were treated with either estrogen or progesterone alone, or in combination for 72 h. The 72 h time point was selected as radiation-induced responses were maximal at this time. Radiation-induced expression of p21/WAF1 was detected in 50% of the ductal epithelial cells in mice receiving both E þ P, but was o1% in mice receiving the vehicle (sesame oil). Treatment with E þ P was more effective in activating p53 than either estrogen or progesterone alone (Figure 2a ; Po0.01) as responsiveness to radiation was reduced in animals receiving estrogen alone (28%) or progesterone alone (9%). The p53-dependence of the responses was confirmed by the absence of p21/WAF expression in BALB/c-Trp53 À/À mice treated with E þ P and radiation (as shown in Figure 1d ).
As treatment with E þ P resulted in similar proportions of cells that were PCNA-positive (59%) and radiation-responsive (50% p21/WAF1-positive) in Figure 1 , a relationship between cycling cells and radiationinduced p53 activity was suggested. However, the individual hormone treatments revealed a dissociation between these parameters. While the proportion of PCNA-positive cells was elevated to a similar extent by estrogen alone or progesterone alone (47 and 38%, respectively), estrogen alone resulted in a significantly larger proportion of cells positive for p21/WAF1 compared to progesterone alone (Figure 2a ; 28 and 9%, respectively). Therefore, recruitment of cells into the cell cycle by E þ P is not sufficient to activate p53-dependent responses to ionizing radiation. Estrogen and progesterone generally act as signaling molecules; however, acute exposure to estrogen can cause formation of adducts in DNA, which may initiate p53 responses. To address this possibility, hormone receptor antagonists were used to determine whether the effects of estrogen and progesterone on p53 occur through their receptors. ICI 182,780 (I) and Mifepristone (M) were used to inhibit the estrogen and progesterone receptors, respectively. These receptor antagonists in combination blocked activation of p53-dependent responses to DNA damage by E þ P (Figure 2b , E þ P þ I þ M). Treatment with Mifepristone did not reduce p21/WAF1 responses to ionizing radiation (Figure 2b ; E þ P þ M). In contrast, cells staining positive for p21/WAF1 after radiation treatment was reduced to 10% when mice received ICI 182,780 together with E þ P (Figure 2b , E þ P þ I). These levels of p21/WAF1 were comparable to the effect of progesterone alone (Figure 2a) , indicating that the estrogen receptor was necessary. The apparent lack of inhibition by Mifepristone alone (E þ P þ M) appears to contrast with the striking inhibition when both Mifepristone and ICI 182,780 were used in combination. As treatment with progesterone alone had only a modest effect on radiation responsiveness (Figure 2a ), blocking progesterone action with Mifepristone may result in a negligible effect. However, Mifepristone can also have stimulatory effects on the estrogen receptor (Jeng et al., 1993; Dibbs et al., 1995) , which would serve to enhance the effect of estrogen in the E þ P þ M treatment. When combined, Mifepristone blocks the activity of progesterone while ICI 182,780 blocks estrogen action as well as the estrogenic effect of Mifepristone resulting in the complete inhibition observed with E þ P þ I þ M. Moreover, the inhibitory effects of receptor antagonists rule out nonspecific effects of E þ P through direct DNA damage. The hormone receptor antagonists ICI 182,780 and Mifepristone also altered proliferative responses of estrogen and progesterone. Treatment with E þ P stimulated active cycling in 60% of mammary epithelial cells, and this effect was abolished by addition of both ICI 182,780 and
Although Mifepristone had no discernable affect on the number of cycling cells induced by E þ P, selective inhibition of estrogen receptor with ICI 182,780 in combination with E þ P reduced the number of cells staining positive for PCNA (Figure 2b , E þ P þ I). This suggests that the estrogen receptor is required for the effects of E þ P as the effect of E þ P þ I mirrored the response to progesterone alone ( Figure 2a ). These results suggest that E þ P enhance p53 activity and proliferation via receptor-mediated pathways.
Levels of p53 mRNA were examined to determine whether the hormone treatments may alter transcription of the p53 gene. There were no differences in steadystate levels of p53 mRNA (P>0.05) among unirradiated tissues ( Figure 3 ). As observed previously , p53 protein was undetectable in unirradiated tissues. These results suggest that estrogen and progesterone initiate a cascade of events that develop over a 72 h period, which serve to enhance the ability of p53 to detect and respond to DNA damage induced by ionizing radiation, but do not increase steady-state levels of p53 mRNA.
As TGF-b1 is required for radiation-responsiveness in the mammary epithelium (Ewan et al., 2002a) , the effects of E þ P may be due to alterations in TGF-b signaling. Levels of phosphorylated Smad2 (P-Smad2) provide an indicator of signaling through the TGF-b receptor. Smad2 was selected because it can regulate the activity of p53 (Cordenonsi et al., 2003) . Western blot analysis showed detectable levels of P-Smad2 in ovariectomized mice and levels were unchanged following irradiation (Figure 4a ). Direct analysis of P-Smad2 expression in the epithelium by immunohistochemical staining showed similar levels and patterns of expression in both vehicle-treated and E þ P-treated mice (Figure 4b ). Importantly, P-Smad2 was expressed primarily within the mammary epithelial cells suggesting that TGF-b acts directly on the mammary epithelium and that basal levels of P-Smad2 are not limiting p53 activity in mammary tissues from ovariectomized mice.
Effects of hormones on whole organ cultures (WOC)
Systemic hormone treatments can act indirectly by influencing endocrine secretions from a variety of tissues such as the pituitary. Therefore, WOC were used to determine if individual growth factors act directly on the mammary gland to alter p53 activity. This cell culture method maintains expression of both the estrogen and progesterone receptors and preserves the ductal architecture that is necessary to recapitulate hormonal regulation of p53 observed in vivo . As growth and development of the mammary gland is regulated by combined effects of mammogenic and lactogenic hormones and growth factors, these factors were tested for their ability to enhance radiation responsiveness of p53 in the presence of E þ P. TUNEL Effects of hormonal stimulation of P-Smad2. Ovariectomized mice were treated with estrogen and progesterone as described in Figure 1 . (a) The lymph nodes were removed from whole mammary glands, then homogenized and analysed for PSmad2 by Western blot. Actin was used as an internal control to normalize for variations in loading. (b) Immunohistochemical staining for P-Smad2 was performed on sections of formaldehydefixed, paraffin-embedded mammary tissues. Immunocomplexes were detected with polymer-linked horseradish peroxidase visualized with DAB (brown staining) and counterstained with Mayer's hematoxylin. Positive-staining nuclei were prevalent in the luminal epithelial cells. Occasional staining was also detected in the stromal cells was used to detect apoptosis because growth regulators such as TGF-b can induce p21/WAF1 directly. In basal media (Control), irradiation resulted in minimal apoptosis (1%; Figure 5a , c). The addition of estrogen and progesterone increased TUNEL-positive nuclei of mammary epithelial cells to 6% (Control þ E þ P; Figure 5a , d). Neither epidermal growth factor (EGF), prolactin (PRL), nor hydrocortisone (HC) provided any enhancement of p53 activity compared to E þ P (Figure 5a ). Triiodothyronine (T3) induced a modest increase (Po0.01) in the proportion of TUNEL-positive cells, possibly through metabolic effects within the gland. These data demonstrate that the enhancement of p53 activity in the mammary epithelium is not a generalized effect of growth factor stimulation, but is specific for E þ P.
While basal levels of signaling through the TGF-b receptors (as determined by P-Smad2; Figure 4 ) were unaltered by treatment with E þ P in vivo, it remained possible that TGF-b may participate in the effects of E þ P on p53 activity. To examine this possibility, WOC were treated with pan-specific anti-TGF-b antibodies to deplete endogenous TGF-b. Antibodies against TGF-b blocked the effects of E þ P (Po0.01) on radiationinduced apoptosis (Figure 5b , e; E þ P þ anti-TGFb), Figure 5 Growth factor requirements for radiation-induced apoptosis in whole organ cultures. (a) Whole organ cultures were maintained in either basal media alone (Control) or supplemented with estrogen and progesterone (E þ P). Additional factors were added to the E þ P-containing media to examine possible additive effects. All cultures were maintained for 96 h. Apoptotic responses to ionizing radiation were determined using the TUNEL method. Concentrations of hormones were 1 ng/ml 17b-estradiol, 1 mg/ml progesterone, 5 ng/ml EGF, 100 ng/ml ovine PRL, 2 mg/ml hydrocortisone, or 8 mg/ml tri-iodothyronine. (b) Whole organ cultures were incubated with either basal media alone (Control), basal media containing estrogen and progesterone (Control þ E þ P), functionblocking antibodies against TGF-b (E þ P þ anti-TGFb), anti-IgG antibodies as a nonspecific control (E þ P þ anti-IgG). Additional tissues were incubated with basal media with E þ P supplemented with TGF-b1 or an equal volume of diluent (E þ P þ 4 mM HCl ¼ 10 ml of 4 mM HCl, 1 mg/ml added to 3 ml media). The effect of TGF-b1 without E þ P was also tested (TGFb alone). Tissues were maintained for 96 h. Apoptotic responses to ionizing radiation were determined using the TUNEL method. Concentrations of hormones were 1 ng/ml 17b-estradiol, 1 mg/ml progesterone, 25 mg/ml anti-TGF-b, 25 mg/ml anti-IgG, 10 ng/ml TGF-b1. Error bars represent s.e.m. Representative images of TUNEL results are shown for Control media (c),
, and h TGFb1 (g). Micrograph images represent Â 200 magnification demonstrating that TGF-b is necessary for activation of p53 by E þ P. This was specific for TGF-b because isotype control antibodies against IgG had no effect (Figure 5b ; E þ P þ anti-IgG). Conversely, addition of exogenous TGF-b1 enhanced radiation-induced apoptosis (Figure 5b, f; TGFb1) . As TGF-b1 requires reconstitution in acidified buffer (4 mM HCl; 1 mg/ml BSA), separate cultures were maintained in equal concentrations of the buffer alone. The buffer control showed no enhancement of apoptosis compared to the treatment with E þ P alone (Figure 5b ; E þ P þ 4 mM HCl vs E þ P-control). The proapoptotic effects of E þ P þ TGF-b treatments following ionizing radiation were p53-dependent as TUNEL was o1% in mammary tissues from BALB/c-Trp53 À/À mice. Though TGF-b is required for activation of p53 by E þ P, treatment with TGF-b1 alone had no effect on p53 responsiveness (Figure 5b , g; þ TGFb1 alone).
Discussion
The absence of radiation-responsiveness in mammary epithelium of ovariectomized mice reveals the important role for estrogen and progesterone in maintaining the ability of p53 to sense and respond to DNA damage. As estrogen and progesterone are mitogenic in the mammary epithelium, enhancing genome surveillance via p53 prior to replication would provide an important 'gatekeeper' function and mitigate the risk associated with proliferation. Indeed, cells in the S phase are more sensitive to radiation-induced DNA damage (Bedford and Dewey, 2002) . Therefore, the close correlation between PCNA-positive cells (a marker of cycling cells) and p53 responsiveness (measured by p21/ WAF1 expression) to ionizing radiation was expected.
However, radiation-induced accumulation of p53 and p21/WAF1 is not strictly linked to cells undergoing mitosis. Mice treated with either E-alone or E þ P resulted in 10 and 31% of mammary epithelial cells being BrdU-positive (Said et al., 1997) . Using Ki-67 as a marker, we observed a similar fraction of cells in the S phase in the E þ P treated mice (28%, data not shown). As the proportion of cells that exhibit nuclear accumulation of p21/WAF1 following ionizing radiation exceeds the fraction of cells that are in the S phase, the effect of estrogen and progesterone cannot be attributed solely to the increased proliferative fraction of cells. Indeed, the proportion of p21/WAF1-positive cells in the mammary epithelium was nearly two-times the expected S-phase fraction. These results are consistent with those in the small intestine where the fraction of p21/WAF1-positive cells exceeded the Sphase fraction (incorporation of 3 H-labeled thymidine) by nearly two-fold (Wilson et al., 1998) . This result would be expected as p53 has a major role in G1 checkpoint function mediated by p21/WAF1. As PCNA levels are elevated in cells that are progressing through G1 as well as cells that are undergoing active DNA synthesis (Celis and Celis, 1985; Iatropoulos and Williams, 1996) , the similar proportions of PCNApositive and p21/WAF1-positive cells following irradiation ( Figure 1) were consistent with expectations.
However, this relationship between cell cycle and radiation-responsiveness appears to be overly simplistic as mitogenic growth factors (EGF, prolactin) failed to enhance p53 activity (Figure 5a) . Therefore, activation of p53 appears to be a specific response to E þ P rather than a general effect of proliferation. Furthermore, the relationship between the fraction of cycling cells and the fraction of cells that exhibit p53-dependent responses to ionizing radiation was disrupted in mice treated with progesterone alone. In mice treated with P-alone, 38% of cells were cycling (PCNA-positive) while only 9% exhibited nuclear accumulation of p21/WAF1 following ionizing radiation. These results suggest that, though progesterone is a potent mitogen in the mammary gland, proliferation is not stringently coupled to enhanced genomic surveillance through p53. This may underscore the tumor-promoting effects attributed to progesterone observed in epidemiologic studies (Schairer et al., 2000) as well as in mice (Lanari et al., 2001) . Although progesterone alone is a relatively modest carcinogen, it promotes rapid onset of aneuploidy followed by tumor formation in p53-deficient mammary epithelium (Goepfert et al., 2000) . The effect of progesterone has been attributed to inappropriate activation of genes involved in separation of sister chromatids together with the loss of checkpoint function due to the absence of p53 (Pati et al., 2004) . These observations suggest that proliferation and activation of p53 are separable pathways and subject to hormonal control.
The downstream effectors of estrogen and progesterone that sensitize p53 and enhance responses to radiation-induced DNA damage were also investigated. Barcellos-Hoff and co-workers (Ewan et al., 2002a) observed low levels of radiation-induced apoptosis in nulliparous mice (ovary-intact) that were similar to reports by our lab . TGF-b1 was implicated as a regulator of p53 activity in these studies as radiation-induced apoptosis was impaired in TGFb1-deficient mice (Ewan et al., 2002a) . Furthermore, ovarian steroids enhance the levels of active TGF-b1 (Ewan et al., 2002b) , suggesting that the effects of E þ P on p53 activity may be mediated by TGF-b. The TGF-b receptors transduce their signals by phosphorylation of several Smads (Massague, 1998) , thus changes in the level of P-Smads provide an indicator of TGF-b signaling. In these studies, P-Smad2 was analysed because it has been shown to augment p53 activity (Cordenonsi et al., 2003) . Levels of P-Smad2 were unchanged in mammary tissue following treatment of mice with E þ P, suggesting that P-Smad2 levels were not rate-limiting for p53 responses (Figure 4) . However, function-blocking antibodies against TGF-b abrogated the effects of E þ P on p53 in mammary epithelial cells in WOC. Although TGF-b was a required co-factor, it was not sufficient to render p53 responsive to ionizing radiation in the absence of E þ P (Figure 5b) . Therefore, crosstalk between intracellular signals induced by estrogen and progesterone and TGF-b is essential for proper regulation of p53 activity in the mammary epithelium. As p53 has been shown to be required for pregnancy-induced prophylaxis of mammary tumors , these data suggest that TGF-b would also be essential for the protective effect of pregnancy.
The mechanisms by which estrogen, progesterone and TGF-b act in the mammary epithelium to sensitize p53 are of intense interest as they represent targets for chemopreventive therapies for breast cancer. The receptors for estrogen, progesterone and TGF-b are coexpressed in a subpopulation of mammary epithelial cells in rodents and humans (Clarke et al., 1997; Russo et al., 1999; Barcellos-Hoff, 2003; Anderson and Clarke, 2004) . Receptor antagonists inhibited the effects of estrogen and progesterone ruling out direct DNA damage (alkylation and epoxidation) by these steroids as a mechanism for increased p53 activity (Figure 2 ). Neither is a direct transcriptional mechanism suggested because E þ P do not alter levels of p53 mRNA in the mammary gland (Figure 3) . Therefore, an indirect pathway is favored in which stability and activity of the p53 protein is regulated by either post-translational modification or interaction with co-factors. The activity of p53 protein is subject to regulation by a large cast of enzymes that phosphorylate, acetylate, sumoylate and ribosylate the p53 protein (Ljungman, 2000; Jerry et al., 2002; Bode and Dong, 2004) . These post-translational changes in p53 can facilitate interactions with co-factors that stabilize the active form of p53 (Waterman et al., 1998; Stavridi et al., 2001) . Heritable breast cancers provide clues to which of these many candidates may be most relevant. Heritable mutations in ATM and CHK2 genes have been identified in some familial breast cancer patients (Meijers-Heijboer et al., 2002; Thorstenson et al., 2003) demonstrating their significance in regulating susceptibility to breast cancer. Both ATM and CHK2 proteins play critical roles in sensing DNA damage and phosphorylate human p53. Therefore, steroid hormones are likely to alter the balance of these enzymes resulting in stabilization and activation of the p53 protein. This stabilization is only apparent in response to DNA damage as hormone treatment alone (without irradiation) does not result in accumulation of active p53 or p21/WAF1 proteins. This feature is important because if exposure to estrogen and progesterone simply increased p53 activity, it would prevent regrowth of the mammary gland during subsequent pregnancies. Instead, estrogen and progesterone can promote mammary gland development, but also enhance genome surveillance by p53 to prevent oncogenic changes.
Alternative pathways are also emerging. The estrogen receptor alpha (ERa) can bind in a ternary complex with HDM2 and p53 proteins leading to stabilization of p53; however, this effect was observed only in overexpression systems and was ligand-independent (Liu et al., 2000) . The p53 protein can also bind ERa and alter transcriptional responses to estrogen (Liu et al., 1999) . Likewise, the DNA binding domain of the progesterone receptor was found to form complexes with DNA-PK in cellular extracts that can phosphorylate p53 (Sartorius et al., 2000) . Alternatively, TGF-b may modify signaling through the receptors for estrogen and progesterone. Smads have been shown to bind ERa (Matsuda et al., 2001; Yamamoto et al., 2002; Wu et al., 2003) and may redirect the signaling to enhance transcription of specific genes that sensitize p53.
While such a signaling cascade could be completed within a few hours following hormonal treatments, it does not provide an answer to why maximal p53-dependent responses were delayed until 72 h after initiation of estrogen and progesterone treatments. The requirement of 72 h to elicit maximal p53-dependent responses suggests the involvement of multiple transcriptional targets downstream of estrogen and progesterone receptors as well as sequential changes in the mammary gland. Gene expression profiling by microarray will likely identify additional components that regulate p53 activity providing novel targets for chemoprevention.
Materials and methods
Hormonal treatment of mice
For the in vivo treatments, virgin BALB/c-Trp53 þ / þ mice were ovariectomized at 8-9 weeks of age. Hormonal treatments were delayed for 1 week following ovariectomy to allow endocrine status to reach baseline. The animals were injected intraperitoneally with 2 mg 17-b-estradiol (E), 1 mg progesterone (P), 200 mg Mifepristone (M), 100 mg ICI 182,780 or 100 ml sesame oil (Vehicle). The E, P, M, and sesame oil were purchased from Sigma (St Louis, MO, USA). The ICI 182,780 was purchased from Tocris (Ellisville, MO, USA). The treatments were administered by intraperitoneal injection in 50-100 ml of sesame oil and repeated daily either singly or in combination for up to 96 h. A minimum of four mice was used for each treatment group. At the end of the treatment period, the animals were subjected to 5 Gy whole-body ionizing radiation using a 137 Cs source. Tissues were harvested 6 h postirradiation. Unirradiated wild-type BALB/c females were used to determine baseline p53 activity in response to treatments. The treatments were replicated in age-matched BALB/c-Trp53 À/À females to assure that effects were p53-dependent. The fourth mammary glands were fixed in 10% neutral-buffered formalin and were embedded in paraffin. All animals were maintained in accordance with procedures approved by the Institutional Animal Care and Use Committee.
Whole organ cultures
For WOC, fourth mammary glands from unprimed, 8-9 week old virgin BALB/c-Trp53 þ / þ and BALB/c-Trp53 À/À mice were removed aseptically, cut in half, then floated on siliconized lens paper in 35-mm tissue culture dishes containing 3 ml of medium. Each tissue culture dish contained the mammary gland halves of four individual mice. Basal medium consisted of serum-free, phenol red-free DMEM/F12 buffered with HEPES and NaHCO 3 , plus 5 mg/ml bovine insulin (GibcoBRL Life Technologies, Carlsbad, CA, USA). Hormone-supplemented media was prepared by adding E þ P (17-b-estradiol, 1 ng/ml; progesterone, 1 mg/ml) to the basal media. Additional growth factors were tested: epidermal growth factor (5 ng/ml, Upstate Biotechnology Inc., Saranac Lake, NY, USA), ovine prolactin (100 ng/ml, NIDDK, NIH), tri-iodothyronine (8 mg/ ml, Sigma), hydrocortisone (2 mg/ml, Sigma). Human TGF-b1 (R&D Systems, Minneapolis, MN, USA) was reconstituted in 4 mM HCl (pH 5.7) containing 1 mg/ml BSA to prepare a 1 mg/ ml stock solution of active growth factor, which was added to media to yield a final concentration of 10 ng/ml. To control for nonspecific effects, tissues were incubated in an equal volume of 4 mM HCl; BSA solution added to basal media. Pan-specific anti-TGF-b antibodies (25 mg/ml, R&D Systems) were added to inhibit TGF-b activity in the WOC. Rabbit anti-mouse IgG (25 mg/ml) was used to control for nonspecific effects of immunoglobulins. WOC were maintained for 96 h in 5% CO 2 : 95% air with media changed daily. After 96 h, the cultures were irradiated (5 Gy), then returned to the incubator for 6 h. Control cultures were handled identically, but not placed in the chamber of the irradiation. The treatments were replicated in age-matched BALB/c-Trp53 À/À females to assure that effects were p53-dependent. The tissues harvested 6 h postirradiation were fixed, and were embedded in paraffin.
Immunohistochemical staining
Rabbit polyclonal antibodies were used for immunohistochemical detection of p21/WAF1 (1 : 50, Oncogene Research Products, San Diego, CA, USA) and p53 (1 : 200, Novacastra, Newcastle, UK). For immunohistochemical detection of PCNA, the mouse monoclonal antibody PC10 (1 : 50, BD Pharmingen, San Diego, CA, USA) was used in combination with the M.O.M. Detection Kit (Vector Laboratories, Burlingame, CA, USA), according to the manufacturer's directions. Tissue sections (4 mm thick) were subjected to microwave antigen retrieval. Immunolabeled complexes were detected using Vector ABC Elite kits (Vector Laboratories) and 3,3 0 -diaminobenzidine (Sigma). Tissue sections were counterstained with methyl green. Apoptosis was detected using the TUNEL method using the FragEL DNA Fragmentation Kit according to the manufacturer's procedures (EMD Biosciences, La Jolla, CA, USA). The responses were quantified by counting 1200 consecutive cells in each section using the Bioquant Imaging Software System (Bioquant Image Analysis Corp, Nashville, TN, USA). Detection of phospho-Smad2 was performed using affinity-purified rabbit polyclonal antibodies (1 : 100, antiSer465/467, Cell Signaling, Beverly, MA, USA) with a polymer-based detection system (Acuity, Signet Laboratories, Dedham, MA, USA) using horseradish peroxidase and DAB counterstained with Mayer's hematoxylin.
Western blot
Flash-frozen tissues were homogenized in RIPA buffer using 1 ml buffer/100 mg tissue. The protein concentration was determined using BCA reagent (Pierce, Rockford, IL, USA).
In total, 150 mg of each sample were loaded on 10% polyacrylamide gels containing SDS and were separated by electrophoresis under reducing conditions. The proteins were transferred to PVDF membranes (Immobilon-P, Millipore, Bedford, MA, USA), then incubated in blocking buffer. Phospho-Smad2 was detected using affinity-purified polyclonal antibodies directed against phospho-Ser465/467 (1 : 1000, Cell Signaling) followed by peroxidase-linked anti-rabbit IgG antibodies from donkey (1 : 5000, Amersham Biosciences, Little Chalfon, Buckinghamshire, UK). The antibody complexes were detected using chemiluminescent reagent (Amersham Biosciences). The blots were stripped using a reducing buffer (0.7% b-mercaptoethanol; 2% SDS; 6.25 mM Tris, pH 6.8) then incubated with goat antiactin antibodies (1 : 500; #I-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA) followed by detection with secondary antibodies (1 : 5000 rabbit anti-goat IgG, Sigma) as described above.
Northern blot hybridization
Tissues for RNA were snap-frozen in liquid nitrogen, then stored at À701C until processing. RNA was extracted by homogenizing the tissues in UltraSpec (BioTecx Laboratories, Houston, TX, USA), 1 ml/100 mg of tissue. RNA was isolated using a modified Chomczynski method (Chomczynski and Sacchi, 1987) , according to the manufacturer's directions. In total, 10 mg of total RNA was separated on a 1.2% agaroseformaldehyde gel, transferred onto a nylon membrane (Zetabind; CUNO, Meriden, CT, USA) and hybridized with a 32 P-labeled cDNA probes. Hybridization signals were quantified with a phosphorimager (Cyclone, Parkard Bioscience, Downers Grove, IL, USA). UV-shadowing was used to assure equal loading (Thurston and Saffer, 1989) .
